Patients receiving treatment with atypical antipsychotics commonly experience weight gain,
which can cause considerable distress and can have deleterious effects on cardiovascular …

Objective: To review published and nonpublished literature describing changes in weight,
glucose homeostasis, and lipid milieu with antipsychotics. Methods: A Medline search was …

Prescribing an antipsychotic for a patient with schizophrenia requires a risk-benefit analysis.
Weight gain has become an issue recently as a result of reports that 2 of the atypical …

Weight gain associated with antipsychotic medication can be a barrier to the overall
improvement of mental health patients due to a discontinuation of treatment. The goal of this …

Metabolic abnormalities such as obesity, diabetes and dyslipidaemia increase the risk of
cardiovascular disease, as well as a number of other adverse long-term health …

Metabolic disturbances and cardiovascular disease are important causes of morbidity and
mortality in patients with severe mental illnesses. Antipsychotic medications are the drug of …

Weight gain has been observed with many of the antipsychotics, including the atypical
antipsychotics. The assessment of whether, and to what degree, a drug causes changes in …

Objectives: To provide an overview of pharmacologic and nonpharmacologic strategies for
antipsychotic-associated weight gain and metabolic disturbance, to identify important areas …

Objectives: To review current evidence for the hypothesis that treatment with antipsychotic
medications may be associated with increased risks for weight gain, insulin resistance …

Background: We performed a retrospective analysis of data involving 121 inpatients to
examine the rate of weight gain during antipsychoticfree periods and during treatment with …